CIPO Patents = 1

EPO Patents = 3

Trademarks = 1

Forward Citations = 14

Loading Chart...

3 inventors (with patents filed for the assignee):

Thomas Sciascia (6 out of 13 patents)

Amale Hawi (1 out of 1 patent)

Shashank Rohatagi (1 out of 1 patent)

4. Jennifer Good (0 patent)

7 patents: Sort by Forward Citations

1. 12274696 - Methods of administering nalbuphine (2025-04-14),

2. 11660296 - Treatment of chronic cough, breathlessness and dyspnea (2023-05-30),

3. 10238646 - Methods for treating pruritus (2019-03-26),

4. 9624233 - Compounds for treating pruritic conditions (2017-04-18),

5. 8987289 - Methods for treating pruritus (2015-03-24),

6. 8940753 - Methods for treating pruritis (2015-01-27),

7. 8637538 - Methods for treatment of pruritis (2014-01-28),

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for serious neurologically mediated conditions. The company's lead candidate, Nalbuphine ER, is being developed for the treatment of chronic pruritus, a severe itching condition. Trevi Therapeutics is dedicated to improving the lives of patients through innovative drug development.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

7 Patents

#32 in New Haven, CT

#779 in Connecticut

#38,840 in US

New Haven, CT, United States of America

Trevi Therapeutics Inc.

Forward Citations = 14

3 inventors:

Thomas Sciascia (6 out of 13 patents)

Amale Hawi (1 out of 1 patent)

Shashank Rohatagi (1 out of 1 patent)

4. Jennifer Good (0 patent)

Please report any incorrect information to support@idiyas.com

1 patent (CIPO):

Please report any incorrect information to support@idiyas.com

3 patents (EPO):

Please report any incorrect information to support@idiyas.com